News | Drug-Eluting Balloons | June 19, 2020

iVascular Launches Essential Pro Coronary Drug-coated Balloon

iVascular Launches Essential Pro Coronary Drug-coated Balloon

June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon (DCB).

The Essential Pro DCB presents several platform improvements from its predecessor such as:
    • Superior safety with fast deflation times due to an increase of the inflation channel and the availability of two different shafts.
    • Better pushability due to an improved transition lumen structure that transmits the whole push to the distal shaft, and uniform transmission due to a new straight distal dual layer shaft design without welds.
    • Improved visibility with metallic radiopaque markers.
    • Improved trackability due to Hydrax plus, iVascular proprietary hydrophilic coating technology. Hydrax plus is applied in the distal shaft, reducing friction during navigation.

The Eessential Pro is indicated for the dilatation of stenosis or coronary artery or bypass grafts occlusions, including small vessels, as well as for residual stenosis after treatment with balloon or endoprosthesis and pre- and post-dilation of coronary endovascular prosthesis.
 

Clinical Study in Small Vessels Using Drug-coated Balloon

An observational, prospective and multicenter registry in small vessels. Baseline characteristics showed a very small diameter of reference (<2.5mm) and high-risk patients (56% diabetics) with only a 12.7% of bailout stenting. In this registry, essential shows a 4.2% TLF at 12-months as a primary endpoint and 9.9% MACE at 12-month as a secondary endpoint. essential demonstrates to be a reliable alternative for small coronary vessels.[1]

Essential DCB Use in Stent Restenosis

An investigator initiated, observational, prospective and multicenter study. DES restenosis was treated in 67% of the cases and a 94% of DCB angiographic success was achieved with only 2 additional stenting. In this study essential shows a 51.4% In-segment maximal area stenosis at 6-month as a primary endpoint and a 13.3% TLF at 24-month as a secondary endpoint. In this study, essential showed a good and sustained efficacy in the treatment of ISR (mostly of DES) maintained on the very long-term.[2]
 
 
For more information: ivascular.global/coronary/essentialpro/
 

References:

1. Rosa Alba Abellas-Sequeiros, Rodés-Cabau J., et al. Percutaneous Coronary Intervention for Treating De-Novo Lesions in Small Coronary Vessels: Initial Experience With the Essential Paclitaxel-Coated Balloon. Coronary Artery Disease. 29(6):477 481, September 2018.

2. J. De La Torre Hernández. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis. Cardiovasc Revasc Med. 2019 Jul 23. pii: S1553-8389(19)30433-6.

 
 

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav